ZURA — Zura Bio Share Price
0.000.00%
Last trade - 00:00- $222.89m
- $147.88m
- 32
- 11
- 22
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.57 | ||
| Price to Tang. Book | 3.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.5% | ||
| Return on Equity | -135.44% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -48.18 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 10th, 2021
- Public Since
- July 16th, 2021
- No. of Shareholders
- 27
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 63,683,806
- Address
- 4225 Executive Square, Suite - 600, SAN DIEGO, 92037
- Web
- https://zurabio.com/
- Phone
- +1 8582470520
- Contact
- Verender Badial
- Auditors
- WithumSmith Brown PC
Upcoming Events for ZURA
Similar to ZURA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Zura Bio share price?
As of Today at 24:19 UTC, shares in Zura Bio are trading at $3.42. This share price information is delayed by 15 minutes.
How has the Zura Bio share price performed this year?
Shares in Zura Bio last closed at $3.42 and the price had moved by -71.4% over the past 365 days. In terms of relative price strength the Zura Bio share price has underperformed the S&P500 Index by -77.25% over the past year.
What are the analyst and broker recommendations for Zura Bio?
The overall consensus recommendation for Zura Bio is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Zura Bio dividend yield?
Zura Bio does not currently pay a dividend.
Does Zura Bio pay a dividend?
Zura Bio does not currently pay a dividend.
When does Zura Bio next pay dividends?
Zura Bio does not currently pay a dividend.
How do I buy Zura Bio shares?
To buy shares in Zura Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zura Bio?
As of the previous close price of $3.42, shares in Zura Bio had a market capitalisation of $217.80m.
Where are Zura Bio shares listed?
Here are the trading details for Zura Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ZURA
What kind of share is Zura Bio?
Based on an overall assessment of its quality, value and momentum Zura Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zura Bio share price forecast for 2024?
The analyst consensus target price for shares in Zura Bio is $17.17. That is 402.05% above the last closing price of $3.42.
Analysts covering Zura Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.52 for the next financial year.
What is the trend in the Zura Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zura Bio. Over the past six months, its share price has underperformed the S&P500 Index by -43.19%.
As of the last closing price of $3.42, shares in Zura Bio were trading -22.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zura Bio PE Ratio?
The Zura Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zura Bio?
We do not have data on Zura Bio's directors